Cefpodoxime Proxetil 200mg
Cefpodoxime Proxetil 200mg tablet — the standard adult dose of the oral third-generation cephalosporin prodrug. Hydrolysed post-absorption to active cefpodoxime, which binds PBPs (particularly PBP1a, PBP1b, PBP3) blocking peptidoglycan synthesis. At 200mg twice daily, achieves plasma concentrations well above the MIC for susceptible organisms including MSSA, S. pneumoniae, H. influenzae, M. catarrhalis, E. coli, Klebsiella, and N. gonorrhoeae. The 200mg dose is bioequivalent to the adult therapeutic target for moderate-to-severe community infections. See PODROCK™ 25 for full mechanism detail.
Standard adult indications for cefpodoxime 200mg: community-acquired pneumonia, acute exacerbations of chronic bronchitis, complicated sinusitis, acute otitis media (adults), pharyngitis and tonsillitis, uncomplicated UTIs, uncomplicated gonorrhoea (200mg single dose), and moderate skin infections including MSSA cellulitis. The 200mg dose is the highest-evidence dose for adult cefpodoxime therapy and is included in standard antibiotic prescribing guidelines for CAP and UTI.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
PODROCK™ 200 is the adult flagship of the PODROCK™ brand range — delivering the full adult dose of cefpodoxime in a single tablet for the most common adult community infections. Its MSSA activity sets it apart from cefixime in the adult outpatient antibiotic segment, making it the preferred oral cephalosporin for physicians managing skin infections, ENT, and pulmonary cases where staphylococcal co-pathogens are clinically relevant.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.